docs/fundraising/meetings/2026-02-18-define-ventures

Meeting: Define Ventures

Date: 2026-02-18 Attendees: Thomas Startz, Michael Yuan, Chuka Esiobu (Define Ventures) Type: Intro Duration: ~21 min


Summary

Short, surface-level intro call. Chuka validated the FDE thesis and payer-first wedge but didn't dig deep on any dimension. Found DaisyAI on a "market map" — wouldn't say which one. Define is an investor in Cohere (concurrent review competitor) — this was not disclosed or discussed despite Thomas raising it at the top. Call pattern is consistent with either a quick screen or competitive intel gathering. Noncommittal close.


Questions Asked

#Question (verbatim/near-verbatim)TopicAnswer QualityNotes
1"Were you guys part of ACM program?"TeamstrongThomas: yes. Michael: lottery. Chuka already familiar with ACM.
2"Which health plan are you guys working with now?"TractiondecentThomas said "West Coast Blue Cross Blue Shield plan" — didn't name Premera but effectively identified it. Would have been better to keep vaguer.
3"How big is the team? Is it just you two for now?"TeamstrongThomas: just us, bootstrapping since graduation. Resonated.
4"Where exactly in the stack are they starting you?"TechnicalstrongThomas: appeals layer. Connected to labor market data (appeals analyst job postings). Good framing.
5"What is your back end look like?"TechnicaldecentThomas: FDE model, working within their systems. Chuka seemed to accept quickly — "fair enough."
6"Are you guys raising anytime soon?"FundraisestrongThomas: yes, raising now. Natural transition.
7"How much?"Fundraisestrong$2M seed. Two more technical hires + Cassie (clinical/ontology lead).
8"How would you want to productize it over time?"Business ModeldecentThomas: licensing agreement for access/maintenance + retainer for FDE work. Referenced SaaS apocalypse. Decent but less crisp than Tau framework.
9"Who else is in pipeline for you guys?"Traction/GTMdecentThomas: focused on current plan, outsourcing groups interested, not pressuring for more FDE clients yet. Honest but revealed thin pipeline.
10"What does success look like? What metrics do they want to track?"TractionweakThomas: haven't gotten to specifics yet. Honest but not great — shows engagement hasn't started.

Concerns Raised

  • Bespoke infrastructure: "Getting into the infrastructure for some of these payers — everyone's very different in their tech stack because they build some of the stuff internally." Implied: hard to scale.
  • Lightweight initial offering: Suggested having something that "doesn't require you to get your hands dirty" as a qualification step. Implied: full FDE engagement might be too heavy for initial customer qualification.

What Resonated

  • FDE thesis: "There's a lot of talk within our ecosystem right now around how do you take this forward deployed approach and really start to transform some of these bespoke workflows." Unprompted validation.
  • Payer starting point: "Payers who are far less likely to buy a wrapper or enterprise SaaS solution. I think where you're starting makes a lot of sense."
  • Platform over point solution: "More and more we are seeing what I'll call platform players in the market... going forward I think both providers and plans are going to want folks that touch a number of different use cases."

Our Commitments

  • Thomas: Send demo and materials

Their Next Steps

  • Chuka: "I'll let you know if it makes sense to connect" at ViVE with a colleague. Noncommittal.

Investor Insights

Define Ventures profile:

  • $800M AUM — largest early stage healthcare player
  • Chuka's background: BCG (0-to-1 team), Define 5+ years
  • Co-founder Lynn was at Kleiner running healthcare
  • Ideation to Series B, $1-20M checks, tend to lead/co-lead
  • Portfolio: Cohere (concurrent review — DIRECT CONFLICT), others unmentioned

The Cohere question: Define is an investor in Cohere, which Thomas has identified as trying to move into concurrent review for 2 years. This was not disclosed or explored in the call. Thomas opened by mentioning excitement about discussing Cohere — Chuka didn't engage on it. The combination of (a) Cohere portfolio, (b) "market map" discovery they won't identify, (c) surface-level questions, (d) specific asks about which plan and where in the stack, and (e) noncommittal close raises the possibility this was competitive intelligence gathering.

Market map signal: Chuka said DaisyAI was "posted on a market map of sorts" and that's how they found them. Couldn't/wouldn't identify which map. This is a meaningful signal regardless of Define's intent — DaisyAI is being tracked and categorized by the market.


Interesting Moments

  • Thomas opened with enthusiasm about Cohere ("the Wharton thing, Define, Cohere — lots of stuff to talk on"). Chuka did not pick up the thread. Could be avoiding the conflict, could be irrelevant to his process.
  • Chuka's advice to "start to map out and work with some folks to get some Intel on the plans that you guys want to target" — generic VC advice or genuine gap he sees.
  • "This is what I do" when asked how he found them — confident, dismissive, didn't elaborate on the market map.
  • Call was 21 minutes. Shortest investor call to date by a significant margin.

Daisy

v1

What do you need?

I can pull up the fundraise pipeline, CRM accounts, hot board, meeting notes — anything in the OS.

Sonnet · read-only